HSBC Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.72M | Sell |
6,100
-9,600
| -61% | -$4.48M | ﹤0.01% | 1397 |
|
|
2025
Q4 | $7.13M | Hold |
15,700
| – | – | ﹤0.01% | 1074 |
|
|
2025
Q3 | $6.14M | Buy |
15,700
+800
| +5% | +$334K | ﹤0.01% | 1108 |
|
|
2025
Q2 | $6.63M | Buy |
14,900
+4,200
| +39% | +$1.94M | ﹤0.01% | 1031 |
|
|
2025
Q1 | $5.17M | Sell |
10,700
-1,200
| -10% | -$559K | ﹤0.01% | 1105 |
|
|
2024
Q4 | $4.79M | Buy |
11,900
+600
| +5% | +$278K | ﹤0.01% | 1150 |
|
|
2024
Q3 | $5.25M | Sell |
11,300
-19,600
| -63% | -$9.42M | ﹤0.01% | 1104 |
|
|
2024
Q2 | $14.6M | Sell |
30,900
-6,500
| -17% | -$2.82M | 0.01% | 761 |
|
|
2024
Q1 | $15.6M | Buy |
37,400
+14,500
| +63% | +$6.13M | 0.01% | 756 |
|
|
2023
Q4 | $9.33M | Sell |
22,900
-13,900
| -38% | -$5.13M | 0.01% | 915 |
|
|
2023
Q3 | $12.9M | Buy |
36,800
+19,000
| +107% | +$6.64M | 0.01% | 758 |
|
|
2023
Q2 | $6.24M | Sell |
17,800
-9,700
| -35% | -$3.27M | 0.01% | 973 |
|
|
2023
Q1 | $8.62M | Sell |
27,500
-2,400
| -8% | -$720K | 0.01% | 906 |
|
|
2022
Q4 | $8.55M | Buy |
29,900
+4,100
| +16% | +$1.25M | 0.01% | 1030 |
|
|
2022
Q3 | $7.52M | Buy |
25,800
+5,500
| +27% | +$1.58M | 0.01% | 1011 |
|
|
2022
Q2 | $5.73M | Buy |
20,300
+14,300
| +238% | +$3.83M | 0.01% | 1141 |
|
|
2022
Q1 | $1.57M | Sell |
6,000
-15,600
| -72% | -$3.7M | ﹤0.01% | 1720 |
|
|
2021
Q4 | $4.76M | Buy |
21,600
+9,100
| +73% | +$1.77M | ﹤0.01% | 1277 |
|
|
2021
Q3 | $2.28M | Buy |
12,500
+8,600
| +221% | +$1.68M | ﹤0.01% | 1478 |
|
|
2021
Q2 | $786K | Buy |
3,900
+900
| +30% | +$188K | ﹤0.01% | 1899 |
|
|
2021
Q1 | $645K | Sell |
3,000
-1,200
| -29% | -$264K | ﹤0.01% | 1833 |
|
|
2020
Q4 | $987K | Sell |
4,200
-15,000
| -78% | -$3.44M | ﹤0.01% | 1717 |
|
|
2020
Q3 | $5.24M | Sell |
19,200
-9,400
| -33% | -$2.59M | 0.01% | 934 |
|
|
2020
Q2 | $8.3M | Sell |
28,600
-40,300
| -58% | -$10.9M | 0.02% | 698 |
|
|
2020
Q1 | $16.3M | Sell |
68,900
-8,300
| -11% | -$1.9M | 0.04% | 429 |
|
|
2019
Q4 | $16.8M | Buy |
77,200
+63,900
| +480% | +$12.9M | 0.03% | 588 |
|
|
2019
Q3 | $2.25M | Buy |
13,300
+12,300
| +1,230% | +$2.18M | ﹤0.01% | 1541 |
|
|
2019
Q2 | $183K | Buy |
+1,000
| New | +$175K | ﹤0.01% | 2574 |
|
|
2019
Q1 | – | Sell |
-5,400
| Closed | -$895K | – | 2899 |
|
|
2018
Q4 | $895K | Hold |
5,400
| – | – | ﹤0.01% | 1847 |
|
|
2018
Q3 | $1.04M | Hold |
5,400
| – | – | ﹤0.01% | 1729 |
|
|
2018
Q2 | $918K | Hold |
5,400
| – | – | ﹤0.01% | 1814 |
|
|
2018
Q1 | $880K | Buy |
+5,400
| New | +$882K | ﹤0.01% | 1692 |
|
|
2017
Q4 | – | Sell |
-15,400
| Closed | -$2.34M | – | 2395 |
|
|
2017
Q3 | $2.34M | Buy |
+15,400
| New | +$2.32M | ﹤0.01% | 1262 |
|
|
2016
Q1 | – | Sell |
-11,000
| Closed | -$1.38M | – | 2247 |
|
|
2015
Q4 | $1.38M | Buy |
+11,000
| New | +$1.33M | ﹤0.01% | 1367 |
|
|
2013
Q3 | – | Sell |
-8,893
| Closed | -$712K | – | 1786 |
|
|
2013
Q2 | $712K | Buy |
+8,893
| New | +$655K | ﹤0.01% | 1146 |
|
Other funds holding VRTX
VCM
VPM
HSBC Holdings's VRTX Position: Q1 2026 in Review
HSBC Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q1 2026, buying an estimated $11.7M and bringing the position to 655,443 shares worth $293M. The position accounts for 0.15% of the portfolio, ranked #119.
HSBC Holdings first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $425M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- HSBC Holdings held 655,443 shares of Vertex Pharmaceuticals worth $293M as of Q1 2026.
- HSBC Holdings bought 25,154 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.7M.
- Vertex Pharmaceuticals made up 0.15% of HSBC Holdings's portfolio in Q1 2026, its #119 holding.
- HSBC Holdings first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- HSBC Holdings's Vertex Pharmaceuticals position peaked at $425M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.